artificial intelligence

MP Group: Outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022′

We are glad to present our outlook on ‘Artificial Intelligence in Target and Biomarker Discovery-2022’. The attached presentation outlines how AI can better elucidate disease biology and assist with building a robust hypothesis for target and biomarker identification. Most clinical trials fail because of poor safety and efficacy resultant from a lack of holistic disease understanding. The traditional approaches are usually unidimensional and fail to account for the complex nature of biology. While we are observing an explosion of healthcare data,…

Continue Reading

Outlook on AI and medical writing

We are glad to present our outlook on ‘AI and medical writing’ that gives an overall perspective on the technological advancements in the medical writing industry. Medical writing is expected to be a $5B+ market with a ~10% CAGR in the next 5 years. However, the industry faces the challenge of high attrition rates and lack of resources. Inefficiencies are further fueled by limited use of automation to reuse content between different regulatory documents and publications as well as limited…

Continue Reading

BioSpectrum Article – Time for Asian pharma to up their AI game!

The excitement around Artificial Intelligence’s (AI) potential to transform the drug discovery process has been building up in the biopharma industry. AI-drug discovery starts-ups have boomed in the last decade and billions of dollars have already been poured on the promise of an efficient and agile drug discovery process. AI has influenced all sectors of the drug discovery value chain. Technologies have come up to analyze numerous medical images, to aggregate information from millions of publications for rapid analytics, to…

Continue Reading
Close Menu